Monitor for any subsequent conversion of this SC 13G to a SC 13D, which would signal activist intent. The 9.9% stake is near the beneficial ownership cap, suggesting potential for further accumulation if the cap is lifted. Also watch for any material agreements or financing arrangements between CVI/Heights and Sunshine Biopharma given the warrant component.
Price Chart
Executive Summary
CVI Investments, Inc. (managed by Heights Capital Management, Inc.) filed a new SC 13G disclosing a 9.9% passive stake in Sunshine Biopharma Inc., consisting of 1,588,266 shares (including 909,090 common shares and shares issuable upon warrant exercise). The filing certifies no intent to influence control, consistent with a passive investment. This is a new position from this filer, though other investors (Alta Partners LLC, L1 Capital Global Opportunities Master Fund) have previously filed 13G amendments on the same issuer.
Key Financial Metrics
Key Facts
- CVI Investments, Inc. disclosed beneficial ownership of 1,588,266 shares of Sunshine Biopharma common stock.
- The stake represents 9.9% of shares outstanding, based on 15,219,383 shares outstanding as of the completion of the offering referenced in the company's Prospectus (Registration No. 333-299274).
- The position includes 909,090 common shares and shares issuable upon exercise of warrants, subject to a 9.99% beneficial ownership limitation.
- Heights Capital Management, Inc. serves as investment manager and may be deemed beneficial owner of all shares owned by CVI Investments.
- The filing certifies under Rule 13d-1(c) that the securities were not acquired to change or influence control of the issuer.
- This is a new SC 13G filing by CVI Investments; prior 13G/A filings on Sunshine Biopharma were by Alta Partners LLC (Oct 5, 2026) and L1 Capital Global Opportunities Master Fund (Aug 14, 2026).
Financial Impact
9.9% passive stake valued at an undisclosed amount; no transaction price disclosed in the filing.
Risk Factors
- Passive stake could convert to activist filing (SC 13D) if investor seeks board representation or strategic changes.
- Warrant overhang (shares issuable upon exercise) could lead to future dilution if exercised.
- Small-cap biotech with multiple institutional filers may indicate concentrated ownership and potential volatility.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| SC 13G Filing (Primary) | 0001649553-26-000116 |
| Document: sbfm_sc13g-ex99.htm | 0001649553-26-000116 |
| Document: 0001649553-26-000116-index-headers.html | 0001649553-26-000116 |
| Document: 0001649553-26-000116-index.html | 0001649553-26-000116 |
| Document: 0001649553-26-000116.txt | 0001649553-26-000116 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 14, 2026 12d ago | SC 13G | $0.2430 $0.2154 | ▼ −11.36% | ▼ −11.81% | — |
Oct 13, 2026 13d ago | SC 13G | $0.2430 $0.2154 | ▼ −11.36% | ▼ −11.81% | — |
Oct 9, 2026 17d ago | 8-K | $0.3020 $0.2418 | ▲ +19.93% | ▲ +18.44% | — |
Oct 9, 2026 17d ago | 424B4 | $0.3020 $0.2418 | ▲ +19.93% | ▲ +18.44% | — |
Oct 8, 2026 18d ago | EFFECT | $0.4300 $0.2300 | ▲ +46.51% | ▲ +46.24% | — |
Oct 5, 2026 21d ago | SC 13G/A | $0.3979 $0.2363 | ▲ +40.61% | ▲ +40.47% | — |
Oct 2, 2026 24d ago | S-1 | $0.4201 $0.3020 | ▲ +28.11% | ▲ +28.53% | — |
Sep 9, 2026 6w ago | EFFECT | $1.12 $1.04 | ▲ +7.59% | ▲ +7.26% | — |
Aug 28, 2026 8w ago | 8-K | $1.12 $1.15 | ▲ +2.68% | ▲ +2.82% | — |
Aug 3, 2026 12w ago | 8-K | $1.17 $1.22 | ▲ +4.27% | ▲ +2.25% | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers